Scleroderma is a chronic autoimmune disease in which the immune system triggers overproduction of collagen, causing the skin and, in some forms, internal organs to thicken and harden. It ranges from a localized form affecting only patches of skin to a systemic form that can involve the lungs, kidneys, heart, and digestive tract. Its exact cause is unknown, and it is substantially more common in women than in men.
Facts
Classification
Body SystemLymphatic or Immune System 1 ICD-10 ChapterIII: Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism 1 Communicable or Non-communicable Transmission Route Causative Agent
Causative Agent (category) First Described Connections
Associated With
Autoimmune connective-tissue disease; rheumatology specialty.
Treated By
Sources
1. Wikipedia: ICD-10
WikipediaList of chapters, Chapter IIIQuote, List of chapters, Chapter III
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
View the Source 2. Wikipedia: Non-communicable disease
WikipediaNamed examples sectionQuote, Named examples section
NCDs include Parkinson's disease, autoimmune diseases, strokes, heart diseases, cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
View the Source 3. Wikipedia: Scleroderma
WikipediaLead - causative-agent
Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs.
Lead section, transmission-route statement
Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs.
View the Source 4. Scleroderma (Wikipedia)
Lead sectionQuote, Lead section
Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs.
View the Source Wikidata: Scleroderma
Wikidata Q958797, label and description confirmed against the entity (w-fix-wikititles2-1002)View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.